Teva Pharmaceutical Industries Limited unit Teva Respiratory has launched its ProAir HFA asthma treatment inhaler with a dose counter for use in patients from age four. The inhaler is for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB). The company said that the ProAir HFA with dose counter supports the U.S. Food and Drug Administration's (FDA) recommendations for such mechanisms, as a means for patients and caregivers to track the number of doses remaining in their inhaler, thus reducing the risk of utilizing an inhaler that no longer contains the medication required at the onset of asthma symptoms.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.26 USD | +0.06% | -4.69% | +55.75% |
06-27 | Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating | MT |
06-25 | Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.75% | 18.42B | |
+55.95% | 819B | |
+43.25% | 638B | |
-6.98% | 351B | |
+19.08% | 329B | |
+9.05% | 298B | |
+17.23% | 242B | |
+2.82% | 225B | |
+13.26% | 217B | |
+8.91% | 168B |
- Stock Market
- Equities
- TEVA Stock
- News Teva Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited Launches Asthma Treatment Inhaler with Dose Counter